RecruitMe Clinical Trial

A Randomized, Double-blind, Placebo-controlled Phase 2 Study of MM-141 plus NabPaclitaxel and Gemcitabine versus Nab-Paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer
A study for patients with metastatic Pancreatic Cancer using study drug MM-141 plus NabPaclitaxel and Gemcitabine
Sponsor:Merrimack Pharmaceuticals
Enrolling:Male and Female Patients
Age Range:Between 18 and 99 years old
IRB Number:AAAQ0008
U.S. Government ID:NCT02399137
Contact: Gulam Manji MD: 646-317-6085 / gam2140@cumc.columbia.edu
Additional Study Information:

This study is for patients with newly discovered metastatic pancreatic cancer. The main purpose of this study is to evaluate whether the combination of MM-141, nabpaclitaxel and gemcitabine works better against tumor cells than nab-paclitaxel and gemcitabine alone in subjects with this pancreatic cancer.

This study is closed
Investigator
Gulam Manji, MD, PhD
You may be eligible for this study

Place Holder




Who Can I Contact?
For more information, please contact:
Gulam Manji MD
Email: gam2140@cumc.columbia.edu
Phone: 646-317-6085